ANI Pharmaceuticals Net Income
| ANIP Stock | USD 81.84 0.34 0.42% |
As of the 7th of February, ANI Pharmaceuticals shows the Risk Adjusted Performance of (0.06), coefficient of variation of (1,141), and Mean Deviation of 1.44. ANI Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
ANI Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.6354 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -16.7 M | -15.8 M | |
| Net Loss | -16.7 M | -15.8 M | |
| Net Loss | -44.6 M | -42.3 M | |
| Net Loss | (0.86) | (0.91) | |
| Net Income Per E B T | 0.75 | 0.51 |
ANI | Net Income | Build AI portfolio with ANI Stock |
Evaluating ANI Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into ANI Pharmaceuticals's fundamental strength.
Latest ANI Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of ANI Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ANI Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of ANI Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ANI Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (18.52 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ANI Net Income Regression Statistics
| Arithmetic Mean | (9,318,398) | |
| Geometric Mean | 11,345,104 | |
| Coefficient Of Variation | (256.79) | |
| Mean Deviation | 19,865,196 | |
| Median | (2,659,415) | |
| Standard Deviation | 23,928,510 | |
| Sample Variance | 572.6T | |
| Range | 80.4M | |
| R-Value | (0.12) | |
| Mean Square Error | 601.4T | |
| R-Squared | 0.02 | |
| Significance | 0.64 | |
| Slope | (587,205) | |
| Total Sum of Squares | 9161.2T |
ANI Net Income History
Other Fundumenentals of ANI Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ANI Pharmaceuticals Net Income component correlations
ANI Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Net Income. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Pharmaceuticals industry sustain growth momentum? Does ANI have expansion opportunities? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ANI Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth (0.17) | Earnings Share 1.6 | Revenue Per Share | Quarterly Revenue Growth 0.536 | Return On Assets |
ANI Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on ANI's balance sheet. Smart investors calculate ANI Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since ANI Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ANI Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ANI Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ANI Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ANI Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ANI Pharmaceuticals.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in ANI Pharmaceuticals on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding ANI Pharmaceuticals or generate 0.0% return on investment in ANI Pharmaceuticals over 90 days. ANI Pharmaceuticals is related to or competes with Harrow Health, CanSino Biologics, Qilian International, Tilray, Dermapharm Holding, Green Thumb, and Trulieve Cannabis. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescrip... More
ANI Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ANI Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ANI Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 13.39 | |||
| Value At Risk | (2.78) | |||
| Potential Upside | 2.77 |
ANI Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ANI Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use ANI Pharmaceuticals historical prices to predict the future ANI Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.41) | |||
| Treynor Ratio | (0.49) |
ANI Pharmaceuticals February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.48) | |||
| Mean Deviation | 1.44 | |||
| Coefficient Of Variation | (1,141) | |||
| Standard Deviation | 2.15 | |||
| Variance | 4.62 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.41) | |||
| Treynor Ratio | (0.49) | |||
| Maximum Drawdown | 13.39 | |||
| Value At Risk | (2.78) | |||
| Potential Upside | 2.77 | |||
| Skewness | 1.72 | |||
| Kurtosis | 9.04 |
ANI Pharmaceuticals Backtested Returns
ANI Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0516, which signifies that the company had a -0.0516 % return per unit of return volatility over the last 3 months. ANI Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm ANI Pharmaceuticals' Risk Adjusted Performance of (0.06), coefficient of variation of (1,141), and Mean Deviation of 1.44 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.41, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ANI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ANI Pharmaceuticals is expected to be smaller as well. At this point, ANI Pharmaceuticals has a negative expected return of -0.11%. Please make sure to confirm ANI Pharmaceuticals' treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if ANI Pharmaceuticals performance from the past will be repeated in the future.
Auto-correlation | 0.28 |
Poor predictability
ANI Pharmaceuticals has poor predictability. Overlapping area represents the amount of predictability between ANI Pharmaceuticals time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ANI Pharmaceuticals price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current ANI Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | 0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 6.21 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ANI Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ANI Pharmaceuticals reported net income of (18.52 Million). This is 105.43% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 103.24% higher than that of the company.
ANI Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.ANI Pharmaceuticals is currently under evaluation in net income category among its peers.
ANI Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ANI Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ANI Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ANI Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ANI Pharmaceuticals' value.| Shares | Macquarie Group Ltd | 2025-06-30 | 423.7 K | Ubs Group Ag | 2025-06-30 | 404.7 K | Ameriprise Financial Inc | 2025-06-30 | 382.6 K | Nuveen, Llc | 2025-06-30 | 371 K | Aberdeen Group Plc | 2025-06-30 | 365.9 K | Tang Capital Management Llc | 2025-06-30 | 317.5 K | Kennedy Capital Management Inc | 2025-06-30 | 267 K | Jpmorgan Chase & Co | 2025-06-30 | 262.9 K | Rubric Capital Management Lp | 2025-06-30 | 257.7 K | Blackrock Inc | 2025-06-30 | 2.6 M | Vanguard Group Inc | 2025-06-30 | 1.3 M |
ANI Fundamentals
| Return On Equity | 0.0866 | ||||
| Return On Asset | 0.0237 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 2.18 B | ||||
| Shares Outstanding | 22.46 M | ||||
| Shares Owned By Insiders | 9.99 % | ||||
| Shares Owned By Institutions | 96.19 % | ||||
| Number Of Shares Shorted | 2.94 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.62 X | ||||
| Price To Sales | 2.22 X | ||||
| Revenue | 614.38 M | ||||
| Gross Profit | 502.34 M | ||||
| EBITDA | 63.12 M | ||||
| Net Income | (18.52 M) | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 624.09 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 24.19 X | ||||
| Cash Flow From Operations | 64.02 M | ||||
| Short Ratio | 5.52 X | ||||
| Earnings Per Share | 1.60 X | ||||
| Price To Earnings To Growth | 1.06 X | ||||
| Target Price | 110.38 | ||||
| Number Of Employees | 897 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 1.84 B | ||||
| Total Asset | 1.28 B | ||||
| Retained Earnings | (100.28 M) | ||||
| Working Capital | 334 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
| Net Asset | 1.28 B |
About ANI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against ANI Stock
| 0.59 | MRK | Merck Company Aggressive Push | PairCorr |
| 0.57 | CSCO | Cisco Systems Earnings Call This Week | PairCorr |
| 0.49 | JNJ | Johnson Johnson | PairCorr |
| 0.43 | RBGPF | Reckitt Benckiser | PairCorr |
| 0.43 | MCD | McDonalds Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.